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 A CO-loaded cSLNs formulation was improved using protamine to enhance performance. 
 The optimal P:DNA:CO-SLN ratio was 2:1:17 for the highest transfection activity. 
 The obtained SLNplexes showed good particle size and zeta potential. 
 Transfection efficiency of the P:DNA:CO-SLNplexes increased more than 200 times. 
  In vitro, the P:DNA:CO-SLN plexes did not have a cytotoxic effect in human cells. 
 
Abstract 
Nanoparticle-mediated plasmid delivery is considered a useful tool to introduce foreign DNA into the cells for 
the purpose of DNA vaccination and/or gene therapy. Cationic solid-lipid nanoparticles (cSLNs) are 
considered one of the most promising non-viral vectors for nucleic acid delivery. Based on the idea that the 
optimization of the components is required to improve transfection efficiency, the present study aimed to 
formulate and characterize cholesteryl oleate-containing solid-lipid nanoparticles (CO-SLNs) incorporating 
protamine (P) to condense DNA to produce P:DNA:CO-SLN complexes as non-viral vectors for gene delivery 
with reduced cytotoxicity and high cellular uptake efficiency. For this purpose, CO-SLNs were used to prepare 
DNA complexes with and without protamine as DNA condenser and nuclear transfer enhancer. The main 
physicochemical characteristics, binding capabilities, cytotoxicity and cellular uptake of these novel CO-SLNs 
were analyzed.  
Positively charged spherical P:DNA:CO-SLN complexes with a particle size ranging from 330.1 ± 14.8 nm to 
347.0 ± 18.5 nm were obtained. Positive results were obtained in the DNase I protection assay with a 
protective effect of the genetic material and 100% loading efficiency was achieved at a P:DNA:CO-SLN ratio 
of 2:1:7. Transfection studies in human embryonic kidney (HEK293T) cells showed the versatility of adding 
protamine to efficiently transfect cells, widening the potential applications of CO-SLN-based vectors, since 
the incorporation of protamine induced almost a 200-fold increase in the transfection capacity of CO-SLNs 
without toxicity. 
These results indicate that CO-SLNs with protamine are a safe and effective platform for non-viral nucleic 
acid delivery. 
 












Gene therapy and DNA vaccines attract attention in the medical, pharmaceutical and biotechnological fields 
due to their applications in the treatment of diseases for which there is currently no effective conventional 
therapy or for the induction of protective cell-mediated immunity against allergens, infectious agents or 
tumoral cells, for which there are no effective and safe licensed vaccines. In this regard, all currently licensed 
vaccines prepared from killed or inactivated whole cells, recombinant proteins or live attenuated 
microorganisms, stimulate the production of protective neutralizing antibodies. However, except for the 
vaccines prepared from live attenuated microorganisms, which raise concerns about their risks (virulence 
reversion), manufacturing process and transport, the others do not preferentially induce cellular immunity [1]. 
Hence, a novel approach to therapy and vaccination is the administration of nucleic acids that modulate the 
expression or suppression of certain proteins, thus reversing the disorder or genetic alteration or inducing 
protective cell-mediated immunity. 
Despite the advances in this field, the application of plasmid DNA to treat human diseases with therapeutic 
or prophylactic purposes have been hampered by the poor clinical outcomes observed. Detrimental factors 
such as low cellular uptake, instability and rapid in vivo degradation by nucleases, unsatisfactory transport to 
the target and ineffective delivery of plasmid DNA to the cell nucleus [2] have prompted researchers to 
develop several strategies to overcome these barriers. 
The development of an efficient carrier for gene-based medicines is thus considered a crucial factor for the 
successful application of genes in the treatment or prophylaxis of several human diseases. The limitations 
associated with the use of viral vectors, which are those related to safety problems (i.e., triggering of immune 
responses, failure in the insertion of the transgene, oncogenesis) and DNA package size limits [3,4] have 
encouraged the development of alternative methods for gene delivery. In this regard, nanotechnology has 
provided novel opportunities to improve the delivery of nucleic acids, using cationic molecules and structures 
such as polymers, lipids, peptides, nanoparticles, and lipid nanoemulsions as non-viral delivery systems [5]. 
All of them can bind nucleic acids and form complexes known as polyplexes or lipoplexes (depending on the 
nature of the cationic system) that can deliver genetic material to cells [6]. Among the advantageous features 
of these non-viral vectors are low toxicity, low immunogenicity, easy preparation, large-scale production, low-










is low during in vivo testing [8], underscoring the need for more effective nanocarrier formulations capable of 
high transfection efficiency without toxicity. 
Cationic solid-lipid nanoparticles (cSLNs) are considered one of the most promising non-viral vectors for 
nucleic acid delivery. cSLNs are colloidal carriers consisting of oil-in-water microemulsions, in which the liquid 
lipid (oil) has been substituted by a solid lipid dispersed in water or in an aqueous surfactant solution [9]. 
cSLNs offer unique properties that make them especially attractive compared to other nanocarriers, such as 
small size, large surface area, the use of biocompatible excipients that minimize the risk of toxicity, the 
possibility of administering them by multiple routes (intramuscular, intravenous, nasal, ocular, oral, 
pulmonary, topical), the capability of transfecting DNA and RNA in vitro and in vivo, the existence of a safe 
and robust manufacturing process that allows efficient scaling for large-scale production, and the capability 
of sterilization by lyophilization [10-14]. 
Nevertheless, the main drawback of cSLN systems that could hinder their implementation for medical 
purposes is their tendency for polydispersity and aggregation during short- and medium-term storage [15]. 
The use of cholesteryl oleate (CO), a cholesterol derivative, in cSLN-nucleic acid formulations to improve 
cytotoxicity and transfection efficiency as a novel avenue for the development of highly efficient and 
biocompatible therapeutic carriers has been recently proposed [16]. In order to improve the capacity of CO-
SLNs to transfect cells, protamine (P) has been previously incorporated to condense DNA and form 
lipoplexes on the nanoparticle surface [17]. 
Protamine is a small polycationic amine derived from the sperm of salmon, with MW~ 4,000–6,000 Da. Almost 
67% of its amino acid composition is arginine, thus contributing to its high alkalinity [18]. Protamine is a 
positively charged nuclear protein that binds to the phosphate backbone of DNA using its arginine-rich 
domain as anchor. DNA is then stabilized and folded into a toroid, an O-shaped structure that may allow for 
dense DNA packaging, in a similar way to histones. Protamine is considered an attractive biopolymer in the 
field of pharmaceutical technology due to its biocompatibility and has been used in several marketed 
pharmaceutical products such as insulin for many years [19]. Protamine is also used as a pharmaceutical 
drug to neutralize heparin after surgery or for the treatment of heparin overdose [20]. Protamine also has cell-
penetrating and nucleus-targeting properties and its sulfated salt has been shown to be a safer and more 
appropriate alternative to poly-L-lysine for condensation, as well as the delivery of plasmid DNA to the 
nucleus [21]. Furthermore, protamine salts have often been used in combination with liposomal preparations 










containing condensed DNA, which is surrounded by a lipid bilayer. The capacity of protamine to promote the 
transfection of retinal cells with cSLNs was also demonstrated [2,25]. The understanding of the mechanism 
by which protamine increases the transfection efficiency of cSLNs was elegantly shown by Delgado et al [25], 
and it was related to the presence of nuclear localization signals (NLS) in the protamine molecule, its 
protection capacity, and a shift in the internalization mechanism from caveolae/raft-mediated to clathrin-
mediated endocytosis. Then, the in vivo usefulness of cSLNs to transfect ocular tissues was finally shown 
using vectors prepared with cSLNs and protamine demonstrating their potential application for the 
management or treatment of degenerative retinal disorders as well as ocular surface diseases, such as X-
linked juvenile retinoschisis [26]. All these properties make protamine a very useful compound for transfection 
approaches.   
Based on this premise, we designed novel cationic ternary nanoparticles for gene delivery, consisting of 
P/DNA complexes adsorbed on the cationic CO-SLN surface in an effort to expand our previous work and 
improve the transfection efficiency of CO-SLN without toxicity, for their future application on gene therapy or 
DNA vaccines.  
Different complexes were prepared by modifying the P:DNA:CO-SLN mass ratios and transfection efficiency 
and cell uptake in human embryonic kidney (HEK293T) cell line were studied. 
2. Materials and methods 
2.1 Production of CO-SLNs 
The CO-SLNs were manufactured using the hot microemulsion technique, as previously described [27]. The 
components of the lipid matrix (41.7% of the formulation) were stearic acid (EMD Millipore, Billerica, MA, 
USA) and cholesteryl oleate (Tokyo Chemical Industry Co., Tokyo, Japan), poloxamer 188 (8.3% of the 
formulation, from EMD Millipore) and the cationic lipid octadecylamine (50% of the formulation, from Acros 
Organics, Geel, Belgium) was used as charged carrier [16]. Briefly, the lipid matrix was melted at a 
temperature above its melting point while the hydrophilic components were separately heated in ultrapure 
water (EMD Millipore). Later, the components were mixed and stirred at the same temperature (80 °C) to 
form a hot emulsion. After stirring for 10 minutes, the microemulsion was dispersed into refrigerated water (4 
°C) in continuous agitation to produce the core solidification of the cSLNs. The emulsion was centrifuged at 
19,000 x g for 15 min and double filtered with 43-48 µm and 7-9 µm qualitative filter papers (FILTER-LAB®, 










cryoprotectant trehalose (5%, w/v) and freeze-dried to improve its stability and feasibility using a Lyobeta 20 
(Telstar, Terrassa, Spain) pilot freeze-drying system. 
Dye-labeled samples were prepared by adding 200 µl of a methanol solution of 2 mg/ml Nile Red (EMD 
Millipore) to the lipid matrix of SLN suspension before melting [28]. Nile Red is a fluorescent dye that interacts 
with lipids and allows them to be visualized without dissolving them [29].  
All assays, except for the fluorescence microscopy studies, were performed using freeze-dried cSLNs re-
dispersed in ultrapure water (3.0 ml). 
2.2 Plasmid DNA constructs 
The plasmid vector expressing the p3X-Κβ-L firefly luciferase protein has been previously described [30]. A 
dual luciferase assay kit (Promega, Ca, USA) was used for the detection of luciferase activity. For 
fluorescence microscopy experiments the pcDNA3.1 + N-eGFP plasmid vector was used (GenScript, 
Piscataway, USA). 
2.3 Formation of lipoplexes 
P:DNA:CO-SLN vectors were made using 1.0 mg/ml protamine sulfate (EMD Millipore.) mixed with 1000 ng 
of p3X-Κβ-L plasmid (0.75 mg/ml), at a ratio of 2:1 (w/w) for 5 min. Then, the P:DNA complex was mixed with 
a suspension of CO-SLNs at room temperature for 20 min, and electrostatic interactions between the P:DNA 
complexes and CO-SLNs led to the formation of P:DNA:CO-SLN vectors. After incubation, the vectors were 
diluted in Dulbecco´s Modified Eagle Medium (DMEM) low-glucose without penicillin/streptomycin or heat-
inactivated fetal bovine serum (FBSi) for the transfection experiments. Different DNA masses were tested, 
i.e. 250 ng, 500 ng, 750 ng and 1000 ng respectively. As control, DNA:CO-SLN vectors were prepared by 
mixing an aqueous solution of the p3X-Κβ-L plasmid (0.75 mg/ml) together with 7.0 µl of the CO-SLN 
suspension (72 µg/µl) at room temperature for 20 min to allow the complex to be formed. After incubation, 
the DNA:CO-SLN complexes were diluted in DMEM low-glucose without antibiotics or FBSi. In all cases, 
different DNA masses were tested, as stated before. 
2.4. Determination of particle size and surface charge (zeta-potential) 
Analyses of CO-SLN sizes were determined by laser diffraction on a Mastersizer 2000 (Malvern Instruments, 
UK) equipped with a 4 mW He–Ne laser (633 nm). For DNA:CO-SLNs and P:DNA:CO-SLN complexes, sizes 











The zeta potential of all formulations was measured by laser Doppler microelectrophoresis in a Zetasizer 
Nano-Z (Malvern Instruments, UK). The zeta-potential values were obtained from the electrophoretic mobility 
of the nanoparticles and lipoplexes under an electric field. Measurements were made in triplicate and 
expressed as millivolts (mV). 
2.5. Morphological analysis by transmission electron microscopy (TEM) 
The surface and content homogeneity of the nanoparticles and lipoplexes was analyzed using TEM. Images 
were acquired from reconstituted CO-SLNs after freeze-drying in the presence of trehalose 5% (w/v) using a 
Tecnai Spirit microscope equipped with a LaB6 cathode (FEI Company, Hillsboro, OR, USA). Images were 
recorded at 120 kV using a 1376 x 1024 pixel CCD Megaview camera. The samples were adsorbed onto 
carbon-coated copper grids and were negatively stained with a 2.0% uranyl acetate solution.   
2.6. Differential scanning calorimetry (DSC) 
The possible interactions of the components in the formulation were assessed using DSC, as previously 
described [31]. Briefly, DSC was performed in a DSC-822e (Mettler Toledo) at a heating rate of 10 °C/min 
over a range from 30 °C to 200 °C using the heat flow method. The samples were weighed into a 40 μl 
aluminum pan, and an empty pan was used as a reference. Dry nitrogen (50 ml/min) was used to perform 
the assay in a nonoxidative atmosphere. 
2.7. Electrophoresis on agarose gel 
Loading efficiency of CO-SLNs with and without P and different DNA masses, as well as protection from 
DNAse I digestion (Roche Diagnostics GmbH, Mannheim, Germany) and DNA plasmid release from the 
vectors were carried out using a 1.0% agarose D-1 gel containing 0.04 µl/ml RedSafe® for nucleic acid 
visualization at 80 V for 45 min. The samples were visualized in a GelDoc® EZ Imager (BioRad®, USA) 
system using BioRad® ImageLab 5.2.1 software. 
For the DNase I protection assay, complexes were prepared to a final mass of 1000 ng of DNA. A 
concentration of 1 U DNase I/2.5 µg DNA was added to DNA:CO-SLN and P:DNA:CO-SLN vectors, and the 
corresponding mixtures were then incubated at 37°C for 10 min. After incubation, a solution of 0.2 M EDTA 
(pH 8.0) was added to a final concentration of 8 mM and heated to stop the reaction at 75°C for 4 min. Then, 
10% SDS was added to the samples to a final concentration of 1.0% to release the DNA from the CO-SLN 
lipoplexes. Finally, the integrity of the DNA in each sample was compared to an untreated DNA control. 










HEK293T cells (human embryonic kidney 293T cells) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). The cells were grown and maintained in DMEM medium with low 
glucose supplemented with 10% v/v of heat-inactivated FBS (Life Technologies Corp., Eugene, OR, USA), 
penicillin/streptomycin, 4 mM L-glutamine and non-essential amino acids, at 37°C in a 95% air and 5% CO2 
atmosphere as previously described [27]. 
For all the biological assays implicating nucleic acids, the complexes were prepared by mixing CO-SLNs with 
the appropriate amount of DNA or P:DNA, as mentioned in the above sections. 
2.9. Cell viability and proliferation assays 
For the viability/cytotoxicity assays, HEK293T cells were grown in 35 mm plates (Falcon Enamelware, 
London, UK) to approximately 60%–70% confluence. After 48 h of incubation with complexes, cells were 
harvested and processed for cytotoxicity of the different lipoplexes using the propidium iodide (PI) test [32]. 
Briefly, HEK293T cells were seeded in 6-well plates (2.5 x105 cells/well) and incubated in DMEM 
supplemented with 10% FBSi at 37°C for 24 h. The culture medium was removed and the nanoparticles and 
lipoplexes were added in DMEM without antibiotics or FBSi and cells were incubated again at 37°C for 48 h. 
Flow cytofluorometric analyses were performed with the vital dye PI (40 µg/ml, EMD Millipore) using a 
FACSCalibur cytometer (BD Biosciences, San Jose, CA, USA). A minimum of 10,000 events was acquired 
gating the forward and side scatters to exclude cell debris and analyzed in FL-3.  
The proliferation assay was determined in 96-well plates using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay after 24, 48 and 72 h of incubation (Roche, Mannheim, Germany). 
The absorbance at λ= 570 nm was determined using an enzyme-linked immunosorbent assay (ELISA) 
reader. 
2.10. In vitro transfection assay 
The transfection efficiency of the vectors was studied in HEK293T cells grown in 6-well plates by seeding the 
cells at 2.5 x105 cells/well and cultured for 24 h as described above. When cells reached approximately 60-
70% of confluence, the medium was changed to a medium without serum or antibiotics.  
The mixture CO-SLN/DNA and CO-SLN/P:DNA was kept at room temperature for 20 min to allow the 
complexes to form before transfection. Lipoplexes were prepared by mixing 1000 ng of the p3X-Κβ-L plasmid, 
and the amounts of CO-SLNs derived from the viability assay as mentioned earlier. The mixtures were added 










48 h after transfection and processed for luciferase activity using the Dual-Luciferase® Reporter Assay 
(Promega Corporation, Madison, WI, USA) protocol following the manufacturer’s instructions.  
Different DNA:CO-SLNs and P:DNA:CO-SLNs w/v and w/w/v ratios respectively were tested (250:7; 500:7; 
750:7, 1000:7 and 500:250:7; 1000:500:7; 1500:750:7; 2000:1000:7).  
Cells transfected with P:DNA at 2:1 w/w ratio were used as control following an identical procedure. 
P:DNA:CO-SLN lipoplexes with a non-coding plasmid for the luciferase enzyme were used as negative 
control. At the end of incubation, cells were collected and lysed with a T7 buffer containing PMSF and DTT 
at 4°C for 30 minutes. After centrifugation at 16,000 x g the supernatant was recovered to measure the activity 
of luciferase. 
2.11. Cellular uptake of non-viral vectors 
The uptake of vectors by HEK293T cells was studied by fluorescence microscopy using an Olympus wide-
field microscope and Cell-R IX81 software. For this purpose, CO-SLNs were labelled using the fluorescent 
dye Nile Red (absorption= 553 nm) and the process continued as described in the in vitro transfection assay. 
Cells were fixed with 3.5% PFA at 4°C for 45 minutes and protected from light after incubation with the 
complexes for 1 h and 24 h. Later, the cells were washed three times with PBS and permeabilized with 0.5% 
Triton X-100 at RT for 5 minutes. Then the cells were washed another three times with PBS and the nuclei 
were stained with DAPI (blue). After two more washes with PBS, preparations were finally mounted with 
ProLong® Gold antifade reagent (Life Technologies Corp.). Plasmid coding for the GFP protein (pcDNA3.1 
+ N-eGFP plasmid) was used to demonstrate the transfection capability of the lipoplexes. Non-Nile Red 
labeled CO-SLNs were used as negative control. Images were converted to a compatible format to 
deconvolve using the Imaris 4.0 software (Bitplane) and then were deconvolved with Huygens Essential 
software 3.4 version. All images were analyzed using Fiji/ImageJ software 1.52i version. 
2.12. Statistical analyses 
Statistical analyses were performed using Prism 5.0 software (GraphPad). Two-tailed Student’s tests 
(unpaired t-test) were used to compare the samples and their respective 
controls. The P values are represented by asterisks (*: P< 0.05; **: P< 0.01; and ***: P< 0.001). The absence 
of an asterisk indicates that the change relative to the control is not statistically significant. 
3. Results 










Particle size ranged from 330.1 ± 14.8 nm to 347.0 ± 18.5 nm and from 856.8 ± 242.6 nm to 1029.9 ± 212.2 
nm in those SLNplexes obtained with and without P, respectively. The PDI was always higher than 0.4 in 
those SLNplexes obtained without P.  
With regard to zeta potential, complexes showed a positive surface (+38.5 ± 1.1 mV for P-containing 
SLNplexes, and +23.2 ± 1.2 mV for non-P-containing SLNplexes). 
The CO-SLNs were manufactured using the hot microemulsion technique which allows to obtain small and 
homogeneous nanoparticles around 180 nm. Due to the instability of the fresh prepared SLN suspensions, 
the reconstituted lyophilized CO-SLN powder was used in all the assays. Nevertheless, after the freeze-
drying process, the same size and positive charge were observed (187 ± 18 nm and +33.3 ± 0.5 mV, 
respectively). 
The SLNplexes sizes varied according to the DNA masses and P:DNA proportion (Figures 1A and B). In 
general, sizes were significantly higher (P< 0.01) for the vectors prepared without P than for the P:DNA:CO-
SLN vectors (around 4 times). 
Vectors without P showed similar size patterns, and became smaller as the DNA quantity increased from 250 
to 1000 ng; however, their sizes remained too large to transfect cells efficiently [28]. 
In the case of SLNplexes with P, their sizes did not change considerably/significantly when the DNA quantity 
increased from 250 to 1000 ng (percentages varied from 6.5% to 0.5%). However, 1000 ng of DNA was used 
to achieve an efficient transfection. Size differences in SLNplexes related to the different proportions of 
P:DNA tested were not observed. Nevertheless, we proposed a 2:1 ratio as the ideal one because an excess 
of P might hinder DNA delivery within the cell nucleus. 
 












Figure 1B. Size of complexes according to different P:DNA proportions. In all cases, the same DNA mass 
and amount of CO-SLNs were used. 
 
The TEM images confirmed the results obtained with the Mastersizer (Figure 2). The CO-SLNs showed 
spherical morphology and homogenous surfaces with particle sizes consistent with those determined 
previously. No aggregates were observed, supporting the stability of the resuspended freeze-dried particles. 
Similarly, P:DNA:CO-SLNs showed spherical morphology with particle sizes larger than their counterpart 
without P:DNA and a monodisperse distribution. In contrast, the TEM images of DNA:CO-SLN lipoplexes 
showed fusion of the CO-SLNs after binding to the DNA, resulting in lipid–DNA particles with undefined 










The compatibility among the components in the formulation was assessed using DSC. The results indicate 
that there are no interactions among cholesteryl oleate, stearic acid, octadecylamine, poloxamer 188 and 
protamine. Mixtures between the components exhibited no exothermic peak, which indicates that there are 
no physical or chemical interactions and thus validates this formulation for further studies (Supplemental file 
1). 
Figure 2. Morphological analysis of CO-SLN (A), DNA:CO-SLN (B) and P:DNA:CO-SLN (C and D) 














The DNA plasmid was partially bound in those vectors without P at DNA masses higher than 2 µg (Figure 
3A), whereas the DNA plasmid was fully bound in all the vectors containing P (Figure 3B). The protection 
capacity of the vectors and their release of DNA were analyzed by the integrity of DNA in agarose gel 
electrophoresis after treatment with DNase I and SDS, respectively. 
Figure 3. Loading efficiency of cSLN (A) and complexes with P (B) at different amounts of plasmid DNA by 
agarose gel electrophoresis. Lanes 1 to 5: DNA only from 1000, 1500, 2000, 2500 and 3000 ng (A B). Lanes 
6 to 10: DNA:CO-SLN complexes with a fixed amount of 7 µl of CO-SLNs and an increasing amount of DNA 
from 1000, 1500, 2000, 2500 and 3000 ng (A). Lanes 6 to 10: P:DNA:CO-SLN complexes with a fixed amount 
of 7 µl of CO-SLNs and a P:DNA w/w ratio of 2:1 from 1000, 1500, 2000, 2500 and 3000 ng of DNA (B). 











The formulations assayed preserved the integrity of the transported DNA (Figure 4), although the band 
corresponding to the supercoiled DNA topoisoform (lower band, which is the most bioactive isoform) was 
more intense in the vectors containing P after treatment with DNase I and SDS. Moreover, all vectors treated 
with SDS were able to release DNA.  
 
Figure 4. Protection of DNA from DNase I by DNA:CO-SLN and P:DNA:CO-SLN complexes at ratios (w/v 
and w/w/v) of 1:7 and 2:1:7, respectively, visualized by agarose gel electrophoresis. Lane M: MW marker: 










SLNs (1:7); Lane 4: P:DNA:CO-SLNs (2:1:7); Lane 5: DNA released from DNA:CO-SLN complexes with SDS 
1%; Lane 6: DNA released from P:DNA:CO-SLN complexes with SDS 1%; Lane 7: DNA:CO-SLNs treated 
with DNase I and SDS 1%; Lane 8: P:DNA:CO-SLNs treated with DNase I and SDS 1%. Different forms of 





3.3. Cell viability 
The cell viability/cytotoxicity of the CO-SLN vectors and their corresponding SLNplexes with and without P 
was studied on HEK293T cells.  As shown in Figure 5A, no toxic effect of all these vectors and SLNplexes 
were observed by the IP test. These results thus suggest that the CO-SLN SLNplexes are not harmful to 
human cells cultured in vitro under the performed experimental conditions. The cytotoxicity against HEK293T 
cells was also studied using the MTT colorimetric cell proliferation assay. While initial low proliferation was 
observed at 48 h after treatment, the cells recovered quickly and showed almost normal viability at a later 
treatment time point (72 h). As it is shown in Figure 5B no significant differences in the cell proliferation were 
observed in those cells exposed during 24h, 48 h and 72 h with the SLNplexes. 
 
Figure 5. (A) Cell viability of HEK293T cells after 48 h of CO-SLN and lipoplex exposure by flow cytometer. 
(B) Proliferation assay in HEK293T at different times (24 h, 48 h and 72 h) after transfection with DNA:CO-












3.4. Cellular uptake and biological activity 
The cellular uptake of SLNplexes and their capability to generate a biological response were tested by the 
luciferase reporter assay, where pDNA driving the expression of the luciferase gene was transfected into 
HEK293T cells. A dose–response effect in the luciferase activity was observed upon transfection with 
different DNA:CO-SLN and P:DNA:CO-SLN mass ratios. As shown in Figure 6A and 6B, the enzymatic 
activity increased upon transfection with higher amounts of DNA, and the formulations containing P induced 
almost a 200-fold increase in the transfection capacity of the CO-SLNs vectors.  
The cellular uptake and localization of the Nile Red-labeled SLNplexes was evaluated by fluorescence 
microscopy after 1 h and 24 h of transfection of HEK293T cells (Figure 7A and 7B respectively). Numerous 
and diffuse red fluorescent dots were observed in the cytoplasm after 1 h of transfection with the P:DNA:CO-
SLNs,  indicating a rapid interaction of the complexes with the cells. Unlike the P-containing CO-SLN 
SLNplexes that showed a homogeneous fluorescent pattern, the red fluorescent signal from the SLNplexes 
not containing P was less homogeneous and with numerous aggregates, supporting the results obtained with 
the different particle sizes of lipoplexes. At 24 h post-transfection, a weak red fluorescent signal was observed 
in the complexes containing and not containing P, indicating their cellular uptake and degradation. In both 
transfection systems we could visualize the expression of GFP and hence the ability of both SLNplexes to 










Figure 6. Comparison between transfection efficiency of DNA:CO-SLNs vs P:DNA:CO-SLNs in HEK293T 
cells by the luciferase reporter assay. After 24 h of confluence, cells were transfected with both systems and 
harvested at 24 h post-transfection to be analyzed (A B). DNA mass was tested from 250 to 1000 ng (A). 
The DNA:CO-SLNs and P:DNA:CO-SLN mass ratio correspond to 1:7 and 2:1:7 respectively (B). Three 
independent experiments were performed in triplicate. ***P< 0.001. 
 
Figure 7. Fluorescence microscopy images of HEK293T cells transfected with Nile Red-labeled (red) 
DNA:CO-SLN and P:DNA:CO-SLN complexes at 1 h (A) and 24 h (B) after transfection. HEK293T cells were 
treated with DAPI (blue) and the DNA plasmid used corresponds to pcDNA3.1 + N-eGFP. The gray images 













The use of the cholesterol derivative CO as a novel excipient for SLN formulations for the development of 
highly efficient and non-toxic nucleic acid delivery carriers has been previously reported [15,16,27]. 
The incorporation of NLS into non-viral vectors was studied by several authors, and it has been shown to 
improve transfection efficiency due to an effect on the nuclear membrane [33-35]. Protamine, a peptide widely 
used to improve lipofection due to its rich content in NLS, is expected to produce an enhancement of the 
transfection efficacy of CO-SLNs associated to their nuclear localization and stabilization against DNase 
degradation [36].  
Therefore, in the present study, the use of protamine was proposed to obtain an improved formula that 
maintains the nanoparticle structure, morphology and nucleic acid binding efficiency while improving both 
viability and transfection efficiency to induce potent biological activity.  
In the present study, a simple fabrication method with inexpensive reagents, which allows a simple procedure 
for potential scale-up production of SLNs was used.  
According to Faneca et al [37], DNA condensation is necessary to facilitate the mobility of DNA molecules as 
well as to prevent them from inter- and intra-cellular degradation. Nevertheless, the transfection efficiency of 
non-viral systems could be limited by the degree of DNA condensation [38]. Thus, the influence of P:DNA:CO-
SLN mass ratios on the transfection efficiency and cell uptake in  HEK293T cell line was also studied to 
evaluate the role of P as an important factor to improve formulation, and thus its further application in gene 
therapy and/or DNA vaccination.  
SLNplexes containing P showed smaller sizes in comparison with those not containing P in all the pDNA:SLN 
ratios tested. Moreover, P lipoplexes showed mean diameters less than 500-700 nm by far below the size of 
DNA:CO-SLNs, which are larger than 1 µm. This size should be suitable for uptake by endocytic processes 
or direct fusion within the cell membrane [39,40]. In fact, cellular uptake could be shown by fluorescence 
microscopy and resulted in the expression of the encoded reporter gene in at least some cells as discussed 
below.  
TEM images of the SLNplexes without P suggested fusion of the CO-SLNs after binding to the DNA, resulting 










With regard to zeta potential, complexes showed a positive surface. This value was about +38.5 ± 1.1 mV 
for P-containing SLNplexes, and +23.2 ± 1.2 mV for non-P-containing SLNplexes. It is generally considered 
that nanoparticles displaying Z-potential outside the range of ± 25 mV have high stability degrees. 
The more positive Z-potential with P-containing SLNplexes provides evidence that the negative charges of 
DNA were almost completely redressed, whereas a less positive charge obtained in the non-P-containing 
SLNplexes indicate partial DNA complexation, results that were also confirmed in the gel electrophoresis 
retardation assays. Thus, the addition of P to form DNA:CO-SLN SLNplexes demonstrated an excellent 
property to promote pDNA condensation, being able to form small complexes, while non-P-containing 
SLNplexes formed large aggregates of DNA:CO-SLNs. In the case of P:DNA:CO-SLNs, the images obtained 
by TEM showed, spherical nanoparticles with homogeneous surfaces, whose sizes were consistent with 
those measured on a Zetasizer Nano ZS90 (below 350 nm in an average diameter), whereas P-free 
complexes exhibited irregular shapes and a variety of sizes that explain the high PDI values determined by 
DLS.  
Overall results thus showed that vectors prepared without P showed a bigger size, higher PDI and lower zeta 
potential than vectors prepared with P. 
A slightly positive zeta potential of SLNplexes is advantageous because it facilitates the interaction with the 
negatively charged cell surface and the cell entry; high positive charges are unfavorable because of severe 
cytotoxic effects [28,41]. In agreement to a previous report using CO-SLNs [31], all the excipients used in the 
present formulation of the cSLNs showed no interactions among the components and, consequently, 
revealed a good compatibility. 
The nucleic acid binding efficiency to the CO-SLNs with and without protamine was assessed using agarose 
gel electrophoresis. The presence of unbound free DNA in the gels reflects the binding capacity of the 
nanoparticles. In the absence of P, when the DNA amount was 1.0-2.0 µg, no free DNA was observed in the 
gel, which indicated that the DNA was completely bound to the CO-SLNs. When 2.5 µg of DNA was used, 
minimal free DNA was observed in the gel, and considerable free DNA was detected in the gel upon loading 
3 µg of DNA. However, when P was added to form the DNA complexes, the DNA was completely bound to 
the CO-SLNs at all DNA concentrations assayed, demonstrating the versatility of P to condense the DNA 
and improving complexation with CO-SLNs. These results confirmed the suitability of CO-SLNs for DNA 
binding observed in previous works [15,16,27] and the enhancement of the binding efficiency by adding P to 










components of the medium, especially from DNase digestion, is considered an important advantage of non-
viral systems used for the delivery of nucleic acids [42]. In order to study the protection capacity of the novel 
SLNplexes with P, we exposed the DNA:CO-SLN and P:DNA:CO-SLN complexes to DNase I at 37°C for 10 
min, and the integrity of the DNA was analyzed by gel electrophoresis. The results demonstrated that all the 
formulations assayed were able to preserve DNA integrity, although the intensity of the band corresponding 
to the supercoiled DNA topoisoform increased in the vectors containing P, indicating that the protection of 
DNA from DNases can be correlated with the degree of nucleic acid condensation. Moreover, all SLN vectors 
treated with SDS were able to release DNA, which is one of the most crucial steps to achieve an optimal CO-
SLNs-mediated transfection assay suggesting that the degree of condensation obtained with P is not 
excessive enough to limit transfection in in vitro assays. Another important aspect to be considered is DNA 
topology, and supercoiled DNA has been reported in the literature to be the most bioactive form, with the 
highest transfection capacity [43]. Interestingly, it was reported that the presence of the linear form of DNA 
topology after treatment with DNAse I observed in the SLNplexes without P is the result of cutting one of the 
DNA double strands of the supercoiled-DNA by DNase I, turning this DNA topology into open circular DNA, 
which in a successive cut, breaks this isoform to the linear one [44]. Thus, the formulations containing P are 
the ones that better protect DNA from DNase I, and thus, the P-formulation should be the most convenient 
for transfection from a DNA topology point of view. 
Bearing these results in mind, cell viability and transfection efficiency were evaluated in order to understand 
how the different CO-SLN SLNplexes using different DNA condensation capacities with or without P 
influenced their in vitro behavior. As size and Z-potential values of these SLNplexes suggested that they 
might be considered suitable for DNA delivery, these non-viral carriers were applied in the transfection and 
fluorescence experiments. In all cases, the percentage of live cells, determined by flow cytometry was close 
to 100% for both the cells treated and not treated with SLNplexes, indicating that these SLNplexes are non-
cytotoxic to human cells under the experimental conditions. 
The ability of the SLNplexes formulated herein to deliver DNA into cells and generate a biological response 
was assessed analyzing the transfection capacity of the CO-SLNs using the p3X-Κβ-L plasmid that codes 
for the firefly luciferase, as reporter system. In order to support these results, fluorescence microscopy was 
used to assess the transfection capacity and the cellular uptake and localization of the SLNplexes. Large and 
few red fluorescent dots were observed in the cytoplasm and in the nucleus after transfection with the 










results obtained with the luciferase reporter assay suggesting that CO-SLNs with and without P can be 
internalized in cells and generate a biological response, GFP expression. Unlike the CO-SLN SLNplexes 
without P that showed numerous aggregates at 1h post-transfection, the red fluorescent signal from the P-
containing SLNplexes was clear and homogeneous. These observations suggest that the P:DNA:CO-SLN 
complexes have a surface that provides cell binding and intracellular uptake. The presence of NLS 
sequences with high arginine content in the protamine molecule is associated to an enhanced DNA entry into 
the nucleus [45,46]. Therefore, these vectors provided protection against nuclease activity, enabling cellular 
uptake, intracellular nucleic acid release and RNA transcription in the nucleus, transport to the cytoplasm, 
and translation into protein, enabling bioactivity. The addition of P to the CO-SLN formulation showed an 
efficient DNA condensation, facilitated the control of the formulation process preventing the formation of 
aggregates and contributed to protection against DNAse degradation. These results confirmed and improved 
previous results using HEK293T cells [16], in which the transfection efficiency of the novel P:DNA:CO-SLN 
complexes increased more than 200 times, which is remarkable for a non-viral delivery system. The highest 
transfection activity was obtained at a P:DNA:CO-SLNs ratio of 2:1:7, which was the one that displayed the 
optimal DNA condensation. Importantly, these P:DNA:CO-SLNplexes did not have a cytotoxic effect in human 
cells under the studied conditions, and the P:DNA:CO-SLN complexes support cell culture for further testing.   
All data demonstrate the capacity of this P-improved formulation to carry and deliver nucleic acids into the 
cytoplasm and nucleus of mammalian cells with high efficiency, making this formulation a promising DNA-
carrier for either therapeutic or prophylactic purposes. The results presented herein encourage the use of 
this novel formulation for further investigations in therapeutic/vaccine research studies. Studies in these fields 
are currently ongoing by our research work.  
Conclusion 
The incorporation of protamine into the CO-SLNs allowed to obtain a versatile nanovector that is able to 
efficiently transfect cells widening the potential applications of SLN-based vectors for gene therapy and/or 
DNA vaccination. The P:DNA:CO-SLN SLNplexes at a ratio of 2:1:7 was considered the optimal formulation 
that reached the equilibrium conditioned by the degree of gene protection, the binding ability of P:DNA to 
CO-SLNs, and the DNA topology for in vitro transfection assays. Further in vivo experiments are needed to 
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